{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:23:50Z","timestamp":1722691430919},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,30]]},"DOI":"10.7759\/cureus.10741","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T19:02:21Z","timestamp":1601492541000},"source":"Crossref","is-referenced-by-count":6,"title":["Multiple System Atrophy \u2013 Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder"],"prefix":"10.7759","author":[{"given":"Juan Fernando","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagari","family":"Bett\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willians","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazmin Carolina","family":"Cozar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25847","article-title":"Multiple system atrophy of the cerebellar type: clinical state of the art","volume":"29","author":"Lin DJ","year":"2014","unstructured":"Lin DJ, Hermann KL, Schmahmann JD. Multiple system atrophy of the cerebellar type: clinical state of the art. Mov Disord. 2014, 29:294-304. 10.1002\/mds.25847","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1311488","article-title":"Multiple-system atrophy","volume":"3","author":"Fanciulli A","year":"2015","unstructured":"Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015, 3:249-263. 10.1056\/nejmra1311488","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2017.10.007","article-title":"Diagnosis of multiple system atrophy","volume":"211","author":"Palma JA","year":"2018","unstructured":"Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci. 2018, 211:15-25. 10.1016\/j.autneu.2017.10.007","journal-title":"Auton Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0159-1","article-title":"A cross-sectional study on drug use in multiple system atrophy","volume":"28","author":"Rey MV","year":"2014","unstructured":"Rey MV, Perez-Lloret S, Pavy-Le Traon A, Meissner WG, Tison F, & Rascol O. A cross-sectional study on drug use in multiple system atrophy. CNS Drugs. 2014, 28:483-490. 10.1007\/s40263-014-0159-1","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70327-7","article-title":"The natural history of multiple system atrophy: a prospective European cohort study","volume":"12","author":"Wenning GK","year":"2013","unstructured":"Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, K\u00f6llensperger M, et al.. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013, 12:264-274. 10.1016\/S1474-4422(12)70327-7","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-015-0728-y","article-title":"The diagnosis and natural history of multiple system atrophy, cerebellar type","volume":"15","author":"Lin DJ","year":"2015","unstructured":"Lin DJ, Hermann KL, Schmahmann JD. The diagnosis and natural history of multiple system atrophy, cerebellar type. Cerebellum. 2015, 15:663-679. 10.1007\/s12311-015-0728-y","journal-title":"Cerebellum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-51892-7.00015-2","article-title":"Sporadic adult-onset ataxia of unknown etiology","volume":"103","author":"Klockgether T","year":"2012","unstructured":"Klockgether T. Sporadic adult-onset ataxia of unknown etiology. Handb Clin Neurol. 2012, 103:253-262. 10.1016\/B978-0-444-51892-7.00015-2","journal-title":"Handb Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00662-8","article-title":"Multiple system atrophy","volume":"2","author":"Wenning GK","year":"2004","unstructured":"Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004, 2:93-103. 10.1016\/S1474-4422(03)00662-8","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.13.2.299","article-title":"Dynamic mutation and human disorders: the spinocerebellar ataxias (review)","volume":"13","author":"Costa Lima MA","year":"2004","unstructured":"Costa Lima MA, Pimentel MMG. Dynamic mutation and human disorders: the spinocerebellar ataxias (review). Int J Mol Med. 2004, 13:299-302. 10.3892\/ijmm.13.2.299","journal-title":"Int J Mol Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01452.x","article-title":"Placebo-controlled trial of riluzole in multiple system atrophy","volume":"13","author":"Seppi K","year":"2006","unstructured":"Seppi K, Peralta C, Diem\u2010Zangerl A, Puschban Z, Mueller J, Poewe W, Wenning GK. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol. 2006, 13:1146-1148. 10.1111\/j.1468-1331.2006.01452.x","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano S","year":"2015","unstructured":"Romano S, Coarelli G, Marcotulli C, et al.. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015, 14:985-991. 10.1016\/S1474-4422(15)00201-X","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000079252","article-title":"Treatment of ataxia in cortical cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study","volume":"52","author":"Gazulla J","year":"2004","unstructured":"Gazulla J, Errea JM, Benavente I, Tordesillas CJ. Treatment of ataxia in cortical cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study. Eur Neurol. 2004, 52:7-11. 10.1159\/000079252","journal-title":"Eur Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-010-0199-0","article-title":"Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study","volume":"9","author":"Takei A","year":"2010","unstructured":"Takei A, Hamada S, Homma S, Hamada K, Tashiro K, Hamada T. Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum. 2010, 9:567-570. 10.1007\/s12311-010-0199-0","journal-title":"Cerebellum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7961-7","article-title":"Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease","volume":"263","author":"Calandra-Buonaura G","year":"2015","unstructured":"Calandra-Buonaura G, Doria A, Lopane G, et al.. Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease. J Neurol. 2015, 263:250-256. 10.1007\/s00415-015-7961-7","journal-title":"J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.00348.x","article-title":"The symptomatic treatment of multiple system atrophy","volume":"9","author":"Colosimo C","year":"2002","unstructured":"Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol. 2002, 9:195-199. 10.1046\/j.1468-1331.2002.00348.x","journal-title":"Eur J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00058-7","article-title":"Natural history of multiple system atrophy in the USA: a prospective cohort study","volume":"14","author":"Low PA","year":"2015","unstructured":"Low PA, Reich SG, Jankovic J, et al.. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015, 14:710-719. 10.1016\/S1474-4422(15)00058-7","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172145","article-title":"Side effects induced by the acute levodopa challenge in Parkinson's disease and atypical parkinsonisms","volume":"12","author":"Vasta R","year":"2017","unstructured":"Vasta R, Nicoletti A, Mostile G, et al.. Side effects induced by the acute levodopa challenge in Parkinson's disease and atypical parkinsonisms. PLoS One. 2017, 12:e0172145. 10.1371\/journal.pone.0172145","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.05.028","article-title":"Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study","volume":"85","author":"Moretti DV","year":"2014","unstructured":"Moretti DV, Binetti G, Zanetti O, Frisoni GB. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study. Neuropharmacology. 2014, 85:284-289. 10.1016\/j.neuropharm.2014.05.028","journal-title":"Neuropharmacology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000183240.47960.f0","article-title":"Placebo-controlled trial of amantadine in multiple-system atrophy","volume":"28","author":"Wenning GK","year":"2005","unstructured":"Wenning GK, Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol. 2005, 28:225-227. 10.1097\/01.wnf.0000183240.47960.f0","journal-title":"Clin Neuropharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000291","article-title":"Efficacy of parenteral amantadine therapy in the treatment of multiple system atrophy with predominant parkinsonism","volume":"41","author":"Friedberg A","year":"2018","unstructured":"Friedberg A, Erikh I, Nassar M, Sprecher E, Schlesinger I. Efficacy of parenteral amantadine therapy in the treatment of multiple system atrophy with predominant parkinsonism. Clin Neuropharmacol. 2018, 41:160-163. 10.1097\/WNF.0000000000000291","journal-title":"Clin Neuropharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1023\/a:1025067912199","article-title":"Brainstem in multiple system atrophy: clinicopathological correlations","volume":"23","author":"Benarroch EE","year":"2003","unstructured":"Benarroch EE. Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol. 2003, 23:519-526. 10.1023\/a:1025067912199","journal-title":"Cell Mol Neurobiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8375-x","article-title":"The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension","volume":"264","author":"Gibbons CH","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, et al.. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017, 264:1567-1582. 10.1007\/s00415-016-8375-x","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine treatment trial in neurogenic orthostatic hypotension","volume":"63","author":"Singer W","year":"2006","unstructured":"Singer W, Sandroni P, Opfer-Gehrking TL, et al.. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006, 63:513-518. 10.1001\/archneur.63.4.noc50340","journal-title":"Arch Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615","article-title":"Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial","volume":"83","author":"Kaufmann H","year":"2014","unstructured":"Kaufmann H, Freeman R, Biaggioni I, et al.. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014, 83:328-335. 10.1212\/WNL.0000000000000615","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni I","year":"2015","unstructured":"Biaggioni I, Freeman R, Mathias CJ, et al.. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015, 65:101-107. 10.1161\/HYPERTENSIONAHA.114.04035","journal-title":"Hypertension"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnp.0000229946.01494.4c","article-title":"Acetylcholinesterase inhibition in patients with orthostatic intolerance","volume":"23","author":"Singer W","year":"2006","unstructured":"Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol. 2006, 23:477-482. 10.1097\/01.wnp.0000229946.01494.4c","journal-title":"J Clin Neurophysiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70088-7","article-title":"Management of neurogenic orthostatic hypotension: an update","volume":"7","author":"Low PA","year":"2008","unstructured":"Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008, 7:451-458. 10.1016\/S1474-4422(08)70088-7","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13260","article-title":"Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial","volume":"24","author":"Schreglmann SR","year":"2017","unstructured":"Schreglmann SR, B\u00fcchele F, Sommerauer M, et al.. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol. 2017, 24:545-551. 10.1111\/ene.13260","journal-title":"Eur J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.51.1.120","article-title":"A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension","volume":"51","author":"Wright RA","year":"1998","unstructured":"Wright RA, Kaufmann HC, Perera R, et al.. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998, 51:120-124. 10.1212\/wnl.51.1.120","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90230-m","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine","volume":"95","author":"Jankovic J","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, et al.. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993, 95:38-48. 10.1016\/0002-9343(93)90230-m","journal-title":"Am J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study","volume":"6","author":"Low PA","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA. 1997, 6:1046-1051. 10.1001\/jama.1997.03540370036033","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21428","article-title":"Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease","volume":"22","author":"Schoffer KL","year":"2007","unstructured":"Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007, 22:1543-1549. 10.1002\/mds.21428","journal-title":"Mov Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)35246-1","article-title":"Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases","volume":"151","author":"Beck RO","year":"1994","unstructured":"Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994, 151:1336-1341. 10.1016\/s0022-5347(17)35246-1","journal-title":"J Urol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.3.371","article-title":"Treatment of erectile dysfunction with sildenafil citrate (viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension","volume":"71","author":"Hussain IF","year":"2001","unstructured":"Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001, 71:371-374. 10.1136\/jnnp.71.3.371","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson KE","year":"2018","unstructured":"Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018, 175:2554-2565. 10.1111\/bph.14205","journal-title":"Br J Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53491-0.00019-5","article-title":"Multiple system atrophy","volume":"117","author":"Wenning GK","year":"2013","unstructured":"Wenning GK, Krismer F. Multiple system atrophy. Handb Clin Neurol. 2013, 117:229-241. 10.1016\/B978-0-444-53491-0.00019-5","journal-title":"Handb Clin Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009372","article-title":"Progression and prognosis in multiple system atrophy presenting with REM behavior disorder","volume":"94","author":"Giannini G","year":"2020","unstructured":"Giannini G, Mastrangelo V, Provini F, et al.. Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. Neurology. 2020, 94:1828-1834. 10.1212\/WNL.0000000000009372","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-015-0279-9","article-title":"Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis","volume":"25","author":"Palma JA","year":"2015","unstructured":"Palma JA, Fernandez-Cordon C, Coon EA, et al.. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res. 2015, 25:69-75. 10.1007\/s10286-015-0279-9","journal-title":"Clin Auton Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients","volume":"4","author":"Boeve BF","year":"2003","unstructured":"Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003, 4:281-284. 10.1016\/s1389-9457(03)00072-8","journal-title":"Sleep Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27018","article-title":"REM sleep behavior disorder in Parkinson's disease and other synucleinopathies","volume":"32","author":"St Louis EK","year":"2017","unstructured":"St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson's disease and other synucleinopathies. Mov Disord. 2017, 32:645-658. 10.1002\/mds.27018","journal-title":"Mov Disord"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24909","article-title":"Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease","volume":"27","author":"Di Giacopo R","year":"2012","unstructured":"Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012, 27:559-561. 10.1002\/mds.24909","journal-title":"Mov Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/40386-multiple-system-atrophy---cerebellar-type-clinical-picture-and-treatment-of-an-often-overlooked-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:47Z","timestamp":1707506627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/40386-multiple-system-atrophy---cerebellar-type-clinical-picture-and-treatment-of-an-often-overlooked-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.10741","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}